Hyman J. Zimmerman Hepatotoxicity State-of-the-Art Lecture with Dr. Einar Bjornsson, Professor and Chief of the Department of Internal Medicine at the National University of Iceland - Hepatotoxicity from Checkpoint Inhibitors, Biologicals, Small Molecules

Biologic drugs are commonly prescribed for autoimmune conditions and malignancies. How do we manage biologics’ effect on the liver? Acute liver failure has been reported in some patients on TNF-alpha inhibitors. Checkpoint inhibitors that modulate T-cell immune reactivity in cancer are frequently associated with liver injury. This session explores monitoring of liver tests, therapy cessation, corticosteroids and other hot topics.

Learning Objectives:

• Review the frequency of hepatotoxicities associated with biologics and numbers needed to harm.
• Discuss the pathophysiology of hepatotoxicity associated with biologics.
• Summarize current approaches to the management of liver injury in patients on biologics.
  

‍